Massive pulmonary thromboembolism during arthroscopic surgery: the important roles of chest compression and endotracheal intubation.

Guoqiang Chen, Qin Xia, Liwei Liu, Cheng Li, Shukun Fu^{*}

Department of Anesthesiology, School of Medicine, Tongji University, Shanghai Tenth People's Hospital, Shanghai, PR China

Abstract

A case of acute massive pulmonary embolism event happened during fracture fixation in our department recently. Shortly after surgery has begun, vital signs of the patient fluctuated emergently, his consciousness was lost, blood pressure and heart rate was once lost in monitor. We immediately started cardiopulmonary resuscitation plans, including setting up advanced life support, chest compressions and cryogenic brain protection strategy, opening center vein to establish a blood pressure, and monitoring central venous pressure and arterial blood pressure. When trying to maintain the vital signs stable, we improved the relevant inspection at the same time. Through a multidisciplinary collaborative diagnosis, acute massive pulmonary embolism was diagnosed. Heparin was given for anticoagulation, and recombinant tissue plasminogen activator was used for thrombolysis treatment. After vital signs were stable, the patient was transferred to the intensive care unit. Then, the disease progressed into multiple organs failure. After treatment for nearly a month, the patient was discharged, without any sequela or complications.

Keywords: Thromboembolism, Arthroscopic surgery, Chest compression, Endotracheal.

Accepted on July 05, 2017

Introduction

Pulmonary Thromboembolism is a common complication of Deep Venous Thrombosis (DVT), they are collectively known as Venous Thromboembolism (VTE). In recent years, though the awareness of Pulmonary Embolism (PE) increases, still there is an existence of misdiagnosis, missed diagnosis or not timely diagnosis, as well as non-standard thrombolysis and anticoagulation treatment in clinical practice.

Epidemiology

Acute PE is the most severe clinical manifestation of VTE. Most existing epidemiology researches study risk factors and the natural course of VTE as a whole. The incidence of it was 100-200/100,000 [1,2].

There can be no symptoms in PE. Sometimes it was diagnosed accidently. Initial manifestation in some PE patients is sudden death. So it is difficult to obtain accurate PE epidemiological data. According to estimates from epidemiological model, in the six countries of the European Union with a population of 454.4 million in 2004, PE caused death to more than 317,000 cases. Among them, the sudden fatal PE accounted for 34%, of whom 59% failed to diagnose before death, only 7% of early death cases were diagnosed before death. The risk of PE is associated with increasing age. In people aged more than 40, for every 10 y increase, incidence of PE increases about 1 time.

In items for prevention and control of pulmonary embolism in China from 1997-2008, PE patients from more than 60 tertiary hospitals registered. There were a total of 18,206 cases in 16,792,182 cases of hospitalized patients diagnosed with PE. The incidence was 0.1% [3].

Susceptible factors

Susceptible factors of VTE include the patient's own factors (mostly permanent factors) and environmental factors (mostly temporary factors). Six weeks to three months of temporary and reversible risk factors (such as surgery, trauma, braking, pregnancy, oral contraceptive or hormone replacement therapy, etc.) may induce VTE, but in the cases of lack of any known risk factors, PE can also occur.

Major trauma, surgery, lower limb fracture, joint replacement and spinal cord injury are the strong inducing factors of VTE; tumor, pregnancy, oral contraceptives, hormone replacement therapy, and center venepuncture are also recognized susceptible factors of VTE. With the deepening of research, new susceptible factors have been found: VTE, as a part of the cardiovascular disease, shares common risk factors (such as smoking, obesity, hyperlipidaemia, hypertension and diabetes) with artery diseases, especially atherosclerosis. Incidence of VTE is much higher in patients with a disease history of myocardial infarction within 3 months, or hospitalized because of heart failure, atrial fibrillation, or atrial flutter. *In vitro* fertilization further increases the risk of VTE related to pregnancy, especially in the early 3 months. Infection is one of the main inducing factors of in-hospital VTE, and blood transfusion and erythropoiesis factors can also increase the risk of VTE. Common susceptible factors are shown in Table 1 [4].

Table 1. Susceptible factors of VTE.

cower limb fracture dospitalization due to heart failure, atrial fibrillation or atrial flutter within 3 nonths dip or knee arthroplasty Severe trauma Myocardial infarction within 3 months Previous VTE history Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors dormone replacement therapy n vitro fertilization infection (respiratory system, urinary system infection or HIV infection) inflammatory bowel disease Tumor Oral contraceptives Stroke paralysis Postpartum
Aspitalization due to heart failure, atrial fibrillation or atrial flutter within 3 months Alip or knee arthroplasty Severe trauma Myocardial infarction within 3 months Previous VTE history Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors formone replacement therapy <i>n vitro</i> fertilization nfection (respiratory system, urinary system infection or HIV infection) nflammatory bowel disease Tumor Dral contraceptives Stroke paralysis Postpartum
dip or knee arthroplasty Severe trauma Myocardial infarction within 3 months Previous VTE history Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors dormone replacement therapy n vitro fertilization Inflammatory bowel disease Tumor Oral contraceptives Stroke paralysis
Severe trauma Myocardial infarction within 3 months Previous VTE history Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors formone replacement therapy n vitro fertilization nfection (respiratory system, urinary system infection or HIV infection) nflammatory bowel disease fumor Cral contraceptives Stroke paralysis Postpartum
Myocardial infarction within 3 months Previous VTE history Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors formone replacement therapy n vitro fertilization Inflammatory bowel disease Fumor Oral contraceptives Stroke paralysis
Previous VTE history Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors formone replacement therapy n vitro fertilization nfection (respiratory system, urinary system infection or HIV infection) nflammatory bowel disease fumor Dral contraceptives Stroke paralysis Postpartum
Spinal cord injury Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy n vitro fertilization nfection (respiratory system, urinary system infection or HIV infection) nflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Medium susceptibility factors (OR 2-9) Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy n vitro fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Oral contraceptives Stroke paralysis
Knee arthroscopic surgery Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy <i>n vitro</i> fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Tumor Dral contraceptives Stroke paralysis Postpartum
Autoimmune disease Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy n vitro fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Blood transfusion Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy <i>n vitro</i> fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Oral contraceptives Stroke paralysis Postpartum
Central venous catheter Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy In vitro fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Chemotherapy Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy <i>n vitro</i> fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Chronic heart failure or respiratory failure Application of erythropoiesis factors Hormone replacement therapy In vitro fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Application of erythropoiesis factors Hormone replacement therapy In vitro fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Hormone replacement therapy n vitro fertilization Infection (respiratory system, urinary system infection or HIV infection) Inflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
n vitro fertilization nfection (respiratory system, urinary system infection or HIV infection) nflammatory bowel disease Fumor Oral contraceptives Stroke paralysis Postpartum
nfection (respiratory system, urinary system infection or HIV infection) nflammatory bowel disease Fumor Oral contraceptives Stroke paralysis Postpartum
nflammatory bowel disease Fumor Dral contraceptives Stroke paralysis Postpartum
Fumor Dral contraceptives Stroke paralysis Postpartum
Dral contraceptives Stroke paralysis Postpartum
Stroke paralysis ² ostpartum
Postpartum
Superficial vein thrombosis
nherited thrombophilia
Neak susceptible factors (OR<2)
Stay in bed>3 d
Diabetes
lypertension
Sedentary condition (such as car or aircraft travel for a long time)
Age increase
aparoscopic surgery (such as laparoscopic cholecystectomy)
Dbesity

Pregnancy

Varicose veins

Note: OR=Odds Ratio, Relative Risk

This pulmonary thromboembolism patient was with multiple risk factors (such as lower limbs surgery, a knee operation, obesity, sedentary, age increase, etc.), and the onset was severe, with the first symptom of shock, so that it was unable to accurately diagnose the cause at the first time. Corresponding symptomatic treatment and life support were the only treatment. Then, with the improvement of relevant inspection and multidisciplinary assist diagnosis, etiology was clear, anticoagulation thrombolysis treatment precise was implemented; the patient was gradually smooth and steady. Since the patient experienced sharp fluctuations in circulation and pulmonary embolism, after transferred to the ICU for further treatment, multiple organs had varying degrees of damage; especially kidney function suffered the worst damage. After treatment and haemodialysis for a month, the patient was discharged, without any complications. We now report the pulmonary embolism case as follows.

Case Report

A 40 y old male patient, injured by car accident, was caused impact trauma of lower limb leading to closed injury of right knee joint, who was then hospitalized with right knee pain and motion limitation. The MRI revealed the right lateral tibial plateau fracture; possibility of right knee lateral collateral ligament injury; right knee effusion. There was nothing unusual in personal history, obstetrical history and family history of this patient. The preoperative examination had nothing special.

The patient was treated with celecoxib to kill pain, lower limb plaster immobilization, without low molecular weight heparin. The patient was distributed to operating room 6 d after trauma, and spinal anesthesia was delivered. In the middle of surgery, the patient experienced sudden chest tightness, sharp chest pain and irritability. The blood oxygen saturation (SPO₂) and heart rate dropped, non-invasive blood pressure (NIBP) was 65/40 mmHg. Ephedrine 15 mg, atropine 0.5 mg and methylprednisolone 160 mg were injected immediately, the patient breathed on his own with tidal volume 400-500 ml. and the lungs bilateral breath sounds were clear and symmetrical. Since the SPO₂ continued to decline, endotracheal intubation was applied to this patient, but the SPO₂ was still only 70-80%. The ETCO₂ maintained at 0-5 mmHg, with the position of endotracheal tube has been confirmed. At this moment, the SPO₂ decreased to 60-70%, NIBP was unavailable and heart rate decreased to 20-30 bpm with ECG in third degree atrioventricular block. Epinephrine 1 mg, heparin sodium 100 mg were injected intravenously, and defibrillation was applied to the patient. Then, the heart rate had returned to normal rhythm and increased to 160 bpm with SPO₂ and NIBP still unavailable. After a few min, the heart rate gradually decreased. The ECG was in profound bradycardia, 20-30 bpm

Massive pulmonary thromboembolism during arthroscopic surgery: the important roles of chest compression and endotracheal intubation

and ventricular escape beats were seen. Atropine 1 mg was injected but had no effect; subsequent epinephrine 2 mg was given to him with chest compression applied. After about 30 times chest compressions, the ETCO₂ suddenly increased from 0-5 mmHg to 30 mmHg and the SPO₂ gradually recovered to 100%. The 12-lead ECG was in sinus rhythm with SIQIIITIII present, and a complete right branch block was diagnosed. Bedside chest radiograph showed nothing different from the preoperative one. Blood gas analysis revealed profound respiratory acidosis and metabolic acidosis (Table 2). The D-dimer value was extremely high (Table 3).

 Table 2. Dynamics parameters of blood gas analysis during the surgery.

Time	рН	PaCO ₂ (mmHg)	PaO ₂ (mmHg)	BE (mmol/L)	HCO ₃ (mmol/L)	SPO ₂
0.529861	6.801	110.5	224	-17	17.2	99
0.577778	6.881	100.4	106	-14	18.8	91
0.600694	6.892	103	92	-13	19.8	87
0.658333	7.014	90.8	60	-8	23.1	74

Table 3. Dynamics parameters of coagulation function during the surgery.

Time	D-dimer (µg/ml)	INR	APTT (s)	PT (s)	Fibrinogen (g/L)
0.64722 2	>10	1.54	>120	18	2.9
0.69236 1	>10	3.65	>120	43.5	<0.5

The patient was diagnosed as massive pulmonary embolism, given recombinant Tissue Plasminogen Activator (rTPA) 100 mg intravenously for thrombolysis, and NaHCO₃ 150 ml was infused twice for correcting acidosis. When the plasma pH ascended to 7.014, the infusing of NaHCO3 had been terminated, in order to avoid intracellular acidosis. Due to hemodynamic instability, epinephrine was given several times repeatedly. The patient was unconscious with dilatation of pupils and disappearance of pupillary reflex. Ice cap was given for cooling, and mannitol for dehydration treatment. The SPO₂ recovered to 100% after chest compressions, then gradually decreased, finally stabilized at about 88%, and the Arterial Blood Pressure (ABP) stabilized at about 100/65 mmHg with dopamine continuous infusion. When the ABP was stabilized, furosemide 40 mg was administrated immediately, but it was not until rTPA infused over, the urine came out. The patient was transferred to ICU for further treatment. He developed acute multiple organ failure after admission to the ICU (Figures 1A-1E). The echocardiography showed dilated right atrium and right ventricle, tricuspid valve with moderate regurgitation, suggesting pulmonary hypertension, diastolic retrogression of left ventricular. After 2 months treatment, the patient was discharged with no sequela left. The surgery was successful without any sequela.



Figure 1. (A) The dynamic change of ALT within 11 d after operation (peaked at the second day, and then decreased till normal); (B) The dynamic change of NT-proBNP within 12 d after operation (peaked at the seventh day, and then decreased); (C) The dynamic change of hs-TNT within 12 d after operation (peaked at the second day, and then decreased till normal); (D) The dynamic change of Creatinine within 40 d after operation (peaked at the eighth day, and then decreased); (E) The dynamic change of D-dimer after operation (decreased rapidly after three days). P.O.D: Post Operative Day.

Discussion

Venous Thromboembolism (VTE) is responsible for the hospitalization of 250,000 Americans annually and represents a significant risk for morbidity and mortality [5].

PE history, superior vena cava syndrome, Deep Vein Thrombosis (DVT) history or family history of DVT, major operations, immobilization for more than 30 d, general anesthesia, malignancy, central venous catheterization, major injuries, foreign body, polycythaemia, thrombocytosis, cor pulmonale, congestive cardiac failure, thoracic outlet syndrome, coagulation disorders and usage of oral contraception pills are considered predisposing factors of PE [6-11]. Patients with immobilized lower limb trauma should take measures to prevent PE, like smoking cessation, low molecular weight heparin, venous filter implantation and early surgery.

In PE, pulmonary arterial pressure is increased following thrombotic obstruction. Vasoconstriction, pulmonary hypertension, right-sided heart failure, and bronchoconstriction may be seen in the advanced stage [12].

Guidelines identify missive PE as acute PE with sustained hypotension (systolic blood pressure<90 mm Hg for at least 15

min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolaemia, sepsis, or Left Ventricular (LV) dysfunction), pulselessness, or persistent profound bradycardia (heart rate<40 bpm with signs or symptoms of shock). Anticoagulation and fibrinolysis were recommended for patients with missive PE and acceptable risk of bleeding complications [13]. But the usage of endotracheal intubation and chest compression in the treatment of missive PE was rarely mentioned.

Our experience with the presented case suggested endotracheal intubation and chest compression played important roles in the rescue of patient with massive PE diagnosed.

Endotracheal intubation and the use of muscle relaxant could ensure the pulmonary ventilation to greatest extent which is extremely important in the missive PE. Endotracheal intubation established the advanced airway for the possible consequent cardiopulmonary resuscitation.

The monitor of $ETCO_2$ could not only confirm the position of endotracheal tube but also estimate the treatment effect of missive PE. In this patient, the $ETCO_2$ jumped from 0-5 mmHg to 30 mmHg strongly suggested that the effective alveolare ventilation had been extremely improved. Moreover, monitor of $ETCO_2$ could evaluate the quality of possible cardiopulmonary resuscitation, which might help the physicians to determine whether more efficient cardiopulmonary resuscitation was needed or the spontaneous circulation had returned [14].

The implementation of chest compression might cause the lifethreatening blood clots to change position or fragment into small pieces, which resulting the pulmonary hemodynamic improvement might play a crucial role in this case of missive PE. Chest compression is easy to implement and effects fast, which is matching the character of emergency rescue for missive PE.

However, we did not deny the importance of anticoagulation and fibrinolysis. Actually, therapeutic anticoagulation was given to the patient during the diagnostic workup to avoid the blood clots growing up. Fibrinolysis was given to him even though the surgery was in progress, because of the hemodynamic instability. Moreover, the implementation of chest compression might cause the life-threatening blood clots to fragment into small pieces, but according to the continuous results of arterial blood gas analysis, the SPO₂ recovered to 100% after chest compressions, then gradually decreased, suggesting the smaller blood clots might entry and block pulmonary small arteries. So without fibrinolysis, the blood clots could not be eliminated completely and the SPO₂ could not stabilize at approximately 88%.

Compared to other biochemical parameters, the renal function was damaged so badly and persistently due to the hypoxia, hypotension, acidosis and the usage of large dose epinephrine that the artificial kidney dialysis had to be applied. It suggested that the protection of renal function was very important in the treatment of missive PE. The usage of haemodialysis in the early stage might be more helpful. In conclusion, our experience with the presented case suggests that endotracheal intubation with monitor of $ETCO_2$ and chest compression should be implemented as soon as possible when the life-threatening missive PE diagnosed. More efforts should be spent on the protection of renal function in the treatment of missive PE. However, more prospective studies are needed.

Acknowledgment

This work was supported in part by Youth Project of Shanghai Health and Family Plan Committee (20144Y0150).

References

- Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
- 2. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-372.
- 3. Yang Y, Liang L, Zhai Z, He H, Xie W, Peng X, Wang C. Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One 2011; 6: e26861.
- 4. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-3069.
- 5. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation 2010; 121: 46-215.
- 6. Coon WW, Willis PW. Thrombosis of axillary and subclavian veins. Arch Surg 1967; 94: 657-663.
- Crawford F, Andras A, Welch K, Sheares K, Keeling D, Chappell FM. D-dimer test for excluding the diagnosis of pulmonary embolism. Cochrane Database Syst Rev 2016; 010864.
- 8. Hess S, Madsen PH. Radionuclide diagnosis of pulmonary embolism. Adv Exp Med Biol 2017; 906: 49-65.
- 9. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Upperextremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004; 110: 1605-1611.

Massive pulmonary thromboembolism during arthroscopic surgery: the important roles of chest compression and endotracheal intubation

- 10. Madsen PH, Hess S. Symptomatology, clinical presentation and basic work up in patients with suspected pulmonary embolism. Adv Exp Med Biol 2017; 906: 33-48.
- 11. Shah MK, Burke DT, Shah SH. Upper-extremity deep vein thrombosis. South Med J 2003; 96: 669-672.
- 12. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, Rauber K, Iversen S, Redecker M, Kienast J. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-1171.
- 13. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK. Management of massive and sub-massive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-1830.
- 14. Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B,

Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010; 122: 729-767.

*Correspondence to

Shukun Fu

- Department of Anesthesiology
- School of Medicine
- Tongji University
- Shanghai Tenth People's Hospital

Shanghai

PR China